Neuropathic Pain News and Research

RSS

Neuropathic pain is a type of pain that is caused by damage to the nervous system following an injury or illness and affects approximately 1% of the population.

GVK Biosciences and Quantitative Solutions to develop and market clinical trial outcome databases

GVK Biosciences (GVK BIO), Asia’s leading integrated research services provider and Quantitative Solutions (QS), a modeling and simulation (M&S) consultancy to the pharmaceutical and biotech industry, announced a strategic partnership to develop and market clinical trial outcome databases.

5 Oct 2009

New drug combination releives neuropathic pain and improves sleep

People who suffer from debilitating neuropathic pain may get more relief and sleep better by combining two commonly-prescribed drugs.

1 Oct 2009

Pfizer to continue its Aricept agreement with Eisai

Pfizer Inc (NYSE: PFE) today announced that its agreement with Eisai to provide Aricept to patients suffering from Alzheimer’s disease will continue without interruption. Under this redefined alliance, which resolves a previously disclosed dispute, Pfizer and Eisai will continue to co-promote Aricept in the U.S., Japan and key markets in Europe, and Pfizer will continue to have an exclusive license to sell Aricept in the other countries where it has rights.

25 Sep 2009

Aegera Therapeutics raises $7 Million for additional working capital

Aegera Therapeutics, a clinical stage biotechnology company focussed on developing targeted therapeutics for oncology and pain, announced today the full drawdown of a $7 Million debt facility provided by Investissement Quebec.

24 Sep 2009

Results from Phase IIb clinical trial evaluating the safety and efficacy of GSK1838262/XP13512 announced

GlaxoSmithKline (NYSE:GSK) and XenoPort, Inc. (Nasdaq:XNPT) today announced top-line results from a Phase IIb clinical trial evaluating the safety and efficacy of GSK1838262/XP13512 (gabapentin enacarbil) for neuropathic pain associated with post-herpetic neuralgia (PHN) in adults.

17 Sep 2009

Six-month period financial results released by Cannasat Therapeutics

Cannasat Therapeutics Inc., a clinical stage pharmaceutical company developing products to treat neurological disorders such as neuropathic pain and schizophrenia, today announced its results for the six months ended June 30, 2009. Unless specified otherwise, all amounts are in Canadian dollars.

1 Sep 2009

Important development in the treatment of multiple sclerosis

A major step forward, with important implications for understanding how to reduce the severity of multiple sclerosis, has been made by scientists at the University of Bristol. The results are published online today in PNAS.

26 Aug 2009

Endocannabinoids found to spread and prolong pain

Imagine that you're working on your back porch, hammering in a nail. Suddenly you slip and hit your thumb instead - hard. The pain is incredibly intense, but it only lasts a moment. After a few seconds (and a few unprintable words) you're ready to start hammering again.

13 Aug 2009

Transcranial MR-guided focused ultrasound for brain disorders a step closer

A team of researchers working at the MR-Center of the University Children's Hospital in Zürich has completed a pilot study using transcranial MR-guided focused ultrasound to treat 10 patients with neuropathic pain.

9 Aug 2009

Compound from coral offers hope fpr neuropathic pain

A compound initially isolated from a soft coral (Capnella imbricata) collected at Green Island off Taiwan, could lead scientists to develop a new set of treatments for neuropathic pain - chronic pain that sometimes follows damage to the nervous system.

4 Aug 2009

Lilly resubmits Cymbalta supplemental NDA for chronic pain to FDA

Eli Lilly and Company has resubmitted its supplemental New Drug Application (sNDA) for Cymbalta (duloxetine HCl) for the management of chronic pain to the U.S. Food and Drug Administration (FDA).

3 Jun 2009

Simple bedside test improves diagnosis of chronic back pain, could guide treatment

A simple and inexpensive method of assessing pain, developed by Massachusetts General Hospital (MGH) researchers, is better than currently used techniques for distinguishing neuropathic pain - pain caused by damage to the nervous system - from other types of chronic back pain.

6 Apr 2009

New standardized tool for the assessment of chronic pain helps distinguish pain subtypes

Joachim Scholz from Massachusetts General Hospital in Boston, USA and his colleagues studied the symptoms and signs of patients with peripheral neuropathic pain (nerve pain such as sciatica) and non-neuropathic (non-nerve) low back pain to identify the best clinical questions and physical tests for diagnosing pain types.

6 Apr 2009

Oxycodone effective against shingles pain

The painkiller oxycodone is effective at treating the acute pain of shingles, an illness that often causes severe pain which can become long-lasting and sometimes even permanent.

26 Mar 2009

Endo Pharmaceuticals licenses investigational drug axomadol from Grunenthal

Endo Pharmaceuticals announced that it has licensed from Grunenthal the exclusive rights to develop and market the investigational drug axomadol in the United States and Canada.

2 Mar 2009

Chili Peppers continue to help unravel mechanism of pain sensation

Capsaicin, the active ingredient in chili peppers, generally is viewed as an irritant that produces a burning sensation when applied to a sensitive area of the body, such as the cornea.

25 Feb 2009

Leconotide, an investigative calcium channel blocker, shows potential as pain treatment

Results of a pre-clinical study of leconotide, an investigative calcium channel blocker, shows it has the potential to be safe, selective, and efficacious as a new non-opioid treatment for pain relief. It also holds promise in multiple drug delivery options including nasal spray, transdermal patch, and pills. Data were presented today at the American Academy of Pain Medicine's 25th Annual Meeting.

29 Jan 2009

Cymbalta (duloxetine HCl) shown to delay new episodes of depression

New data suggest that Cymbalta (duloxetine HCl) 60 mg to 120 mg once daily delayed the onset of a new episode of depression in patients who had previously responded to the medication and who had recurrent depressive disorder, defined in the study as those patients who experienced at least three depressive episodes in the previous five years, compared with placebo (p < .001).

14 Dec 2008

$Proteolix announces positive data for carfilzomib in patients with relapsed and refractory multiple myeloma$

Proteolix announces positive data for carfilzomib in patients with relapsed and refractory multiple myeloma

Proteolix, Inc. today announced positive clinical data demonstrating that the company's lead product, carfilzomib, has single-agent activity and promotes durable responses in patients with relapsed and refractory multiple myeloma.

10 Dec 2008

Eli Lilly withdraws application for additional U.S. indication for Cymbalta for chronic pain

Eli Lilly and Company has withdrawn its supplemental New Drug Application (sNDA) from the U.S. Food and Drug Administration (FDA) for Cymbalta (duloxetine HCl) for the management of chronic pain.

30 Nov 2008